581 related articles for article (PubMed ID: 15723612)
1. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
Langley B; Gensert JM; Beal MF; Ratan RR
Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
[TBL] [Abstract][Full Text] [Related]
2. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
3. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
Anne-Laurence B; Caroline R; Irina P; Jean-Philippe L
Subcell Biochem; 2007; 41():263-93. PubMed ID: 17484132
[TBL] [Abstract][Full Text] [Related]
4. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
Ganai SA; Banday S; Farooq Z; Altaf M
Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
[TBL] [Abstract][Full Text] [Related]
5. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
6. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
Gray SG; Dangond F
Epigenetics; 2006; 1(2):67-75. PubMed ID: 17998807
[TBL] [Abstract][Full Text] [Related]
7. The role of histone deacetylases (HDACs) in human cancer.
Ropero S; Esteller M
Mol Oncol; 2007 Jun; 1(1):19-25. PubMed ID: 19383284
[TBL] [Abstract][Full Text] [Related]
8. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
Kazantsev AG; Thompson LM
Nat Rev Drug Discov; 2008 Oct; 7(10):854-68. PubMed ID: 18827828
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
Sadri-Vakili G; Cha JH
Curr Alzheimer Res; 2006 Sep; 3(4):403-8. PubMed ID: 17017871
[TBL] [Abstract][Full Text] [Related]
11. Targeting histone acetylation for neuroprotection.
Contestabile A
Curr Pharm Des; 2013; 19(28):5017-8. PubMed ID: 23448467
[No Abstract] [Full Text] [Related]
12. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE
Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
Konsoula Z; Barile FA
J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
[TBL] [Abstract][Full Text] [Related]
14. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.
Marson CM
Anticancer Agents Med Chem; 2009 Jul; 9(6):661-92. PubMed ID: 19601748
[TBL] [Abstract][Full Text] [Related]
16. Histone acetylation and the cell-cycle in cancer.
Wang C; Fu M; Mani S; Wadler S; Senderowicz AM; Pestell RG
Front Biosci; 2001 Apr; 6():D610-29. PubMed ID: 11282573
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors and cancer: from cell biology to the clinic.
Hess-Stumpp H
Eur J Cell Biol; 2005 Mar; 84(2-3):109-21. PubMed ID: 15819394
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases.
Sharma S; Sarathlal KC; Taliyan R
CNS Neurol Disord Drug Targets; 2019; 18(1):11-18. PubMed ID: 30289079
[TBL] [Abstract][Full Text] [Related]
19. Histone acetylation and disease.
Timmermann S; Lehrmann H; Polesskaya A; Harel-Bellan A
Cell Mol Life Sci; 2001 May; 58(5-6):728-36. PubMed ID: 11437234
[TBL] [Abstract][Full Text] [Related]
20. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]